Recro Pharma to Host Analyst and Investor Day on February 28, 2018
February 21 2018 - 7:00AM
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty
pharmaceutical company focused on therapeutics for the hospital and
other acute care settings, today announced that it will host an
Analyst and Investor Day on Wednesday, February 28, 2018 from 9:30
am to 12:00 pm ET in New York City.
The agenda will include an in-depth discussion
of the Company’s commercialization strategy and launch plans for IV
meloxicam 30mg, upon approval, as well as a recap of key clinical
data and regulatory status. The program will also feature key
opinion leaders in the field of pain management and surgery,
including:
- Eugene R. Viscusi, MDDirector, Acute Pain
Management, Thomas Jefferson University
- Richard Iorio, MDChief of Adult
Reconstruction
Kindly RSVP to Janet Cushey at
janet@argotpartners.com to reserve a seat or for additional
information.
A live and archived webcast of the event will be
available on the Events page of the Company’s website at
www.recropharma.com. The webcast will be archived for a period of
60 days following the conclusion of the live event.
About Recro Pharma, Inc.
Recro Pharma is a specialty pharmaceutical
company that operates through two business divisions, an Acute
Care, hospital product division and a revenue-generating contract
development and manufacturing, or CDMO division, located at the
Company’s Gainesville facility. The Acute Care division is
primarily focused on developing innovative products for hospital
and other acute care settings. The Company’s lead product candidate
is a proprietary injectable form of meloxicam, a long-acting
preferential COX-2 inhibitor. IV meloxicam 30mg has
successfully completed two pivotal Phase III clinical efficacy
trials in patients following bunionectomy and abdominoplasty
surgeries, a large double-blind placebo-controlled Phase III safety
trial, four Phase II clinical trials for the management of moderate
to severe post-operative pain, as well as other safety
studies. As injectable meloxicam is in the non-opioid class
of drugs, the Company believes it will overcome many of the issues
associated with commonly prescribed opioid therapeutics, including
respiratory depression, constipation, excessive nausea and
vomiting, as well as having no addictive potential while
maintaining meaningful analgesic effects for relief of pain. The
Company’s CDMO division leverages its formulation expertise to
develop and manufacture pharmaceutical products using its
proprietary delivery technologies and other manufacturing services
for commercial partners who commercialize or plan to commercialize
these products. These collaborations can result in revenue streams
including royalties, profit sharing, research and development and
manufacturing fees, which support continued operations for its CDMO
division and contribute non-dilutive funding for the development
and pre-commercialization activities of its Acute Care
division.
Cautionary Statement Regarding Forward Looking
Statements
This press release contains forward-looking statements that
involve risks and uncertainties. Such forward looking
statements reflect Recro's expectations about its future
performance and opportunities that involve substantial risks and
uncertainties. When used herein, the words "anticipate,"
"believe," "estimate," "upcoming," "plan," "target", "intend"
and "expect" and similar expressions, as they relate to Recro or
its management, are intended to identify such forward-looking
statements. These forward looking statements are based on
information available to Recro as of the date of this press
release and are subject to a number of risks, uncertainties, and
other factors that could cause Recro’s performance to differ
materially from those expressed in, or implied by, these
forward looking statements. Recro assumes no obligation to update
any such forward-looking statements. Factors that could cause
Recro’s actual performance to materially differ from those
expressed in the forward-looking statements set forth in
this press release include, without limitation: the ability to
obtain and maintain regulatory approval of injectable
meloxicam and the labeling under any such approval;
regulatory developments in the United States and foreign
countries; results and timing of the clinical trials of
injectable meloxicam, the Company’s ability to achieve its
financial goals, including financial guidance; the Company’s
ability to raise future financing for continued development,
product commercialization and the payment of milestones; the
Company’s ability to pay its debt; customer product
performance and ordering patterns, the performance of
third-party suppliers and manufacturers; the Company’s ability to
obtain, maintain and successfully enforce adequate patent and
other intellectual property protection; and the successful
commercialization of injectable meloxicam. The forward looking
statements in this press release should be considered together with
the risks and uncertainties that may affect Recro’s business
and future results included in Recro’s filings with the
Securities and Exchange Commission at www.sec.gov.
CONTACT:
Investor Relations Contact:Argot PartnersSusan
Kim/Natalie Wildenradt(212)
600-1902susan@argotpartners.comnatalie@argotpartners.com
Recro Pharma, Inc.Michael Celano(484)
395-2413mcelano@recropharma.com
Media Contact:Argot PartnersDavid Rosen(212)
600-1902david.rosen@argotpartners.com
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From Apr 2023 to Apr 2024